What were the main drivers of revenue growth in the first quarter of 2000?

Revenue growth was primarily driven by strong performance in key therapeutic categories. The CLARITIN line of antihistamines continued its robust sales increase (up 18%), significantly boosting the Allergy & Respiratory segment. Additionally, the Anti-infective & Anticancer segment saw substantial growth, fueled by INTRON A and REBETOL, along with the recent launch of TEMODAR. International sales growth, even with currency fluctuations, also contributed positively.

How is the company managing its cash and shareholder returns?

Schering-Plough generated strong operating cash flow of $636 million in the quarter. The company is actively repurchasing shares, having completed a $1 billion program and initiating a new $1.5 billion authorization. Furthermore, the quarterly dividend was increased by 12% to $0.14 per share, demonstrating a commitment to returning value to shareholders.

Are there any significant legal or regulatory issues that investors should be aware of?

Yes, the company is involved in several ongoing legal and regulatory matters. These include multiple antitrust actions related to prescription drug pricing, investigations by the FTC regarding pricing and marketing practices, and significant patent litigation concerning CLARITIN and CLARITIN-D, with multiple generic manufacturers challenging patent validity. The company is also addressing FDA Warning Letters related to manufacturing issues for aerosol products and has recalled certain products. While the company believes it will prevail in these matters, they represent potential risks and uncertainties.

What is the company's outlook for the remainder of 2000?

Management is optimistic about the full year 2000, expecting to deliver strong earnings performance in line with the current analyst consensus of $1.64 per share. This outlook is supported by continued growth in key product lines and ongoing R&D investments. However, potential headwinds include the impact of foreign currency exchange rate fluctuations and the uncertainties surrounding ongoing legal and regulatory proceedings.

MRK 10-Q Quarterly Report Q1 FY2000 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation reported strong financial results for the first quarter of 2000, with net sales increasing by 10% to $2.4 billion and diluted earnings per share growing 17% to $0.42. This growth was primarily driven by robust performance in key therapeutic areas, notably allergy and respiratory products, where CLARITIN sales surged 18%. The company also saw significant gains in anti-infective and anticancer products, boosted by INTRON A and REBETOL, and the launch of TEMODAR. Despite a decrease in over-the-counter product sales due to a divestiture, overall sales growth outpaced promotional spending, leading to improved operating margins and a higher income before taxes. The company demonstrated solid cash flow generation, with operating activities providing $636 million. While capital expenditures were $100 million and dividends paid were $184 million, Schering-Plough continued its commitment to shareholder returns by repurchasing $355 million in common shares and announcing an additional $1.5 billion repurchase program. Management anticipates continued growth for the full year 2000, projecting earnings per share in line with analyst consensus. However, investors should note potential headwinds from foreign currency fluctuations and ongoing legal and regulatory matters, including patent litigation and government investigations.

Key Highlights

1Net sales grew 10% year-over-year to $2.4 billion in Q1 2000.
2Diluted Earnings Per Share (EPS) increased by 17% to $0.42 compared to $0.36 in Q1 1999.
3CLARITIN sales showed strong growth, up 18% to $665 million, contributing significantly to the 10% rise in Allergy & Respiratory product sales.
4Anti-infective & Anticancer products saw a 17% increase in sales, driven by INTRON A, REBETOL, and the launch of TEMODAR.
5Operating cash flow was robust at $636 million, an increase of over 400% from the prior year.
6The company is actively returning capital to shareholders, having completed a $1 billion share repurchase program and announcing a new $1.5 billion program, alongside a 12% increase in its quarterly dividend.
7Research and Development spending increased by 11% and is expected to rise approximately 15% for the full year 2000, indicating continued investment in innovation.

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2000

Summary

Key Highlights

Frequently Asked Questions